Nausea, vomiting, and diarrhea are common side effects, but clinical trials reveal that severe gastrointestinal adverse reactions affect 4.1% of WEGOVY-injection patients, while only 0.9% of placebo groups experience these issues
While dedicated endometriosis trials have not yet been completed, the mechanism is consistent with benefits seen across the GLP-1 class and early observational data from women in trial settings has included reports of reduced pelvic pain and inflammation
Lasso Peptides: Exploring the Folding Landscape of Natures Smallest Interlocked Motifs
Semaglutide also has evidence for cardiovascular risk reduction, while Wegovy was approved in 2025 for MASH with moderate-to-advanced liver fibrosis
Important safety information Explore Brand-Name GLP-1 Medications Wegovy (brand-name semaglutide) Semaglutide works by binding to GLP-1 receptors, which can help regulate blood sugar levels, slow gastric emptying, and reduce appetite
A 2021 phase 3 clinical trial revealed that individuals receiving 2.4 mg weekly injections of semaglutide experienced a mean weight loss of 14.9%, compared to 2.4% with placebo, over 68 weeks
